MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-07-11
DOI
10.1038/s41598-017-06098-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biomarkers of Renal Tumors: the Current State and Clinical Perspectives
- (2017) Marina O. Golovastova et al. Current Urology Reports
- Non–Clear Cell Renal Cancer: Features and Medical Management
- (2017) Daniel Y. C. Heng et al. Journal of the National Comprehensive Cancer Network
- Itch promotes the neddylation of JunB and regulates JunB-dependent transcription
- (2016) Haiwen Li et al. CELLULAR SIGNALLING
- The expression of Cullin1 is increased in renal cell carcinoma and promotes cancer cell proliferation, migration, and invasion
- (2016) Ji-Gen Ping et al. TUMOR BIOLOGY
- MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma
- (2016) Yi Zhang et al. Oncotarget
- Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells
- (2016) Huiyin Lan et al. Scientific Reports
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
- (2015) Ronan T. Swords et al. BRITISH JOURNAL OF HAEMATOLOGY
- MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies
- (2015) Kuan-Lin Kuo et al. CANCER LETTERS
- Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target
- (2015) Qiang Gao et al. Oncotarget
- Induction of p21-Dependent Senescence by an NAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression
- (2015) Lijun Jia et al. NEOPLASIA
- Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy
- (2014) Yongchao Zhao et al. ANTIOXIDANTS & REDOX SIGNALING
- The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells
- (2014) J. C. Godbersen et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer
- (2014) Lihui Li et al. JNCI-Journal of the National Cancer Institute
- Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles’ heel in mantle cell lymphoma
- (2014) M A Dengler et al. Cell Death & Disease
- The covalent modifier Nedd8 is critical for the activation of Smurf1 ubiquitin ligase in tumorigenesis
- (2014) Ping Xie et al. Nature Communications
- Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
- (2013) S. T. Nawrocki et al. CLINICAL CANCER RESEARCH
- The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth
- (2012) Z. Luo et al. CANCER RESEARCH
- MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
- (2012) Steffan T Nawrocki et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells
- (2012) C Mackintosh et al. ONCOGENE
- Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor
- (2011) D. Wei et al. CANCER RESEARCH
- Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover
- (2011) M. A. Milhollen et al. CANCER RESEARCH
- SCF E3 Ubiquitin Ligases as Anticancer Targets
- (2011) L. Jia et al. CURRENT CANCER DRUG TARGETS
- Independent Validation of the 2010 American Joint Committee on Cancer TNM Classification for Renal Cell Carcinoma: Results From a Large, Single Institution Cohort
- (2011) Simon P. Kim et al. JOURNAL OF UROLOGY
- Quantitative Proteomic Analysis of Cellular Protein Modulation upon Inhibition of the NEDD8-Activating Enzyme by MLN4924
- (2011) Hua Liao et al. MOLECULAR & CELLULAR PROTEOMICS
- NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells
- (2010) J. J. Lin et al. CANCER RESEARCH
- Mechanism-Based Neddylation Inhibitor
- (2010) Matthew D. Petroski CHEMISTRY & BIOLOGY
- Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
- (2010) James E. Brownell et al. MOLECULAR CELL
- RING Domain E3 Ubiquitin Ligases
- (2009) Raymond J. Deshaies et al. Annual Review of Biochemistry
- DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival
- (2009) Timothy R. Peterson et al. CELL
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Novel substrates and functions for the ubiquitin-like molecule NEDD8: Figure 1
- (2008) Dimitris P. Xirodimas BIOCHEMICAL SOCIETY TRANSACTIONS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started